Skip to content

Study · Non-randomized trial · n = 17 · 1996

5 results

Desmopressin in the management of nocturia in patients with multiple sclerosis. A double-blind, crossover trial.

Valiquette G, Herbert J, Maede-D'Alisera P

Archives of neurology1 Dec 1996Cited by 60 (Europe PMC)

PMID8970454 (opens in a new tab)DOI10.1001/archneur.1996.00550120082020 (opens in a new tab)PepBankPUB-08970454
Publisher pagePubMedAsk about this study
Jump to 5 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study5

5 results from studies that gave the peptide. 5 results from people.

  1. 01HumanNon-randomized trialSafety outcome

    In patients with multiple sclerosis, 4 of 17 discontinued the desmopressin study after asymptomatic or minimally symptomatic hyponatremia.

    In plain wordsIn patients with multiple sclerosis, 4 of 17 left the desmopressin study after low blood sodium developed.

    Peptide
    Desmopressin
    Outcome
    Not applicableDiscontinuation due to hyponatremia
    Study

    n = 17

    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    Patients discontinuing after hyponatremia
    4 patients
    17 patients enrolled

    Source sentences

    Summary
    Four of the 17 patients discontinued participation in the study after developing asymptomatic or minimally symptomatic hyponatremia.
    2 context sentences
    Summary · context
    Seventeen patients were enrolled in a double-blind, crossover trial of desmopressin administered at bedtime.
    Summary · context
    Night time voiding diaries were maintained for the 6 weeks of the trial; similarly, serum electrolyte levels and plasma osmolality were measured twice weekly and urinalyses and urine cultures were performed weekly during the trial.
  2. 02HumanNon-randomized trialSafety outcome

    In patients with multiple sclerosis, hyponatremia occurred in 4 of 17 and appeared dose related during desmopressin treatment.

    In plain wordsIn patients with multiple sclerosis, 4 of 17 developed low blood sodium with desmopressin, which appeared dose related.

    Peptide
    Desmopressin
    Outcome
    Not applicableHyponatremia
    Study

    n = 17

    Outcome group
    Adverse events · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    Patients with hyponatremia
    4 patients
    17 patients enrolled

    Source sentences

    Summary
    The only adverse effect attributed to desmopressin was hyponatremia, which occurred in 4 of 17 patients and appeared to be dose related.
    2 context sentences
    Summary · context
    Seventeen patients were enrolled in a double-blind, crossover trial of desmopressin administered at bedtime.
    Summary · context
    Night time voiding diaries were maintained for the 6 weeks of the trial; similarly, serum electrolyte levels and plasma osmolality were measured twice weekly and urinalyses and urine cultures were performed weekly during the trial.
  3. 03HumanNon-randomized trialEfficacy outcome

    In patients with multiple sclerosis, desmopressin reduced nights with nocturia from 97% to 66%.

    In plain wordsIn patients with multiple sclerosis, nights with nocturia decreased from 97% to 66% with desmopressin.

    Peptide
    Desmopressin
    Outcome
    DecreaseNights with nocturia
    Study

    n: not reported in source

    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    Nights with nocturia
    97%
    starting value
    Nights with nocturia
    66%
    with desmopressin

    Source sentences

    Summary
    Desmopressin reduced the percentage of nights with nocturia in patients from 97% to 66%.
    3 context sentences
    Summary · context
    These results were highly significant.
    Summary · context
    Seventeen patients were enrolled in a double-blind, crossover trial of desmopressin administered at bedtime.
    Summary · context
    Night time voiding diaries were maintained for the 6 weeks of the trial; similarly, serum electrolyte levels and plasma osmolality were measured twice weekly and urinalyses and urine cultures were performed weekly during the trial.
  4. 04HumanNon-randomized trialEfficacy outcome

    In patients with multiple sclerosis, nocturia episodes decreased from 2.35 to 1.09 per night during desmopressin treatment.

    In plain wordsIn patients with multiple sclerosis, nightly nocturia episodes decreased from 2.35 to 1.09 with desmopressin.

    Peptide
    Desmopressin
    Outcome
    DecreaseNocturia episodes per night
    Study

    n: not reported in source

    Outcome group
    Urinary continence and bladder function · Kidney and urinary
    Studied dose
    Dose not stated

    Measurements

    Nocturia episodes per night
    2.35 episodes per night
    starting value
    Nocturia episodes per night
    1.09 episodes per night
    with desmopressin

    Source sentences

    Summary
    The average number of episodes of nocturia per night in patients decreased from 2.35 to 1.09 and the maximum hours of sleep uninterrupted by nocturia increased from 3.74 to 5.77.
    3 context sentences
    Summary · context
    These results were highly significant.
    Summary · context
    Seventeen patients were enrolled in a double-blind, crossover trial of desmopressin administered at bedtime.
    Summary · context
    Night time voiding diaries were maintained for the 6 weeks of the trial; similarly, serum electrolyte levels and plasma osmolality were measured twice weekly and urinalyses and urine cultures were performed weekly during the trial.
  5. 05HumanNon-randomized trialEfficacy outcome

    In patients with multiple sclerosis, maximum sleep uninterrupted by nocturia increased from 3.74 to 5.77 hours during desmopressin treatment.

    In plain wordsIn patients with multiple sclerosis, maximum uninterrupted sleep increased from 3.74 to 5.77 hours with desmopressin.

    Peptide
    Desmopressin
    Outcome
    IncreaseUninterrupted sleep
    Study

    n: not reported in source

    Outcome group
    Sleep · Sleep
    Studied dose
    Dose not stated

    Measurements

    Maximum uninterrupted sleep
    3.74 hours
    starting value
    Maximum uninterrupted sleep
    5.77 hours
    with desmopressin

    Source sentences

    Summary
    The average number of episodes of nocturia per night in patients decreased from 2.35 to 1.09 and the maximum hours of sleep uninterrupted by nocturia increased from 3.74 to 5.77.
    3 context sentences
    Summary · context
    These results were highly significant.
    Summary · context
    Seventeen patients were enrolled in a double-blind, crossover trial of desmopressin administered at bedtime.
    Summary · context
    Night time voiding diaries were maintained for the 6 weeks of the trial; similarly, serum electrolyte levels and plasma osmolality were measured twice weekly and urinalyses and urine cultures were performed weekly during the trial.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:35 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.